I disagree. The Montifiore release is them touting their involvement which promotes Leronlimab, but it is clearly written to give them credit for introducing the drug (which they did). I see very little unbiased 3rd party validation or even speculation at this point. The articles we are mostly seeing are not medical journals but rather investment advice. That's fine, but we need credibility and validity in the medical world. Considering we only have 45 patients in our lead trial, there is still an enormous disconnect.